Oncology | Blood Cancer

Partner with us for reliable CALR mutation detection

CALR gene mutations in MPNs

Somatically acquired calreticulin (CALR) mutations occur in 20–25% of Philadelphia-negative (Ph–) myeloproliferative neoplasms (MPNs) (1). This discovery not only provides an additional relevant clonal marker, it also gives hope for new treatment options.

Sensitive detection of CALR mutations has enormous potential to help us better understand this previously uncharacterized molecular marker. This drives advances in blood cancer clinical research and pioneers breakthrough treatments.

Female scientist working in a laboratory

In addition to our comprehensive blood cancer assays, we also offer sublicenses to our CALR intellectual property for laboratory-developed test workflows. If you are interested in sublicensing options for detection of CALR mutations, simply contact us to find out more.

Reliably detect CALR mutations

We acquired an exclusive worldwide license for intellectual property rights covering certain mutations in the CALR biomarker from the Research Center for Molecular Medicine (CeMM), Vienna.

Our CALR RGQ PCR Kit (RUO) (cat. no. 674013) is an important part of our comprehensive range of assays for blood cancer clinical research.

This kit enables detection of CALR exon 9 mutations. It provides specific and simultaneous identification of the two main CALR mutations (type 1 and type 2). This takes place in a single real-time PCR step using the Rotor-Gene Q 5plex HRM.

Discover more

Did you know, we also have an exclusive license for intellectual property rights covering the JAK2 V617F mutation, which is present in 50–97% of patients with Ph– MPNs?

The CALR RGQ PCR Kit is For Research Use Only. Not for use in diagnostics procedures. No claim or representation is intended to provide information for the diagnosis, prevention, or treatment of a disease.

QIAGEN is the exclusive licensee of intellectual property rights that cover the detection of specific mutations in the CALR gene for diagnostic purposes. These intellectual property rights contain granted US patent US 11,274,350 and corresponding patents and pending patent applications in US and other countries.

Reference

1. Wu Z, Zhang C, Ma X, Guan M. Clinical relevance between CALR mutation and myeloproliferative neoplasms. Stem Cell Investig. 2015 Feb 16;2:4. doi: 10.3978/j.issn.2306-9759.2015.01.03. PMID: 27358872; PMCID: PMC4923639.